about
Genome-wide scan identifies TNIP1, PSORS1C1, and RHOB as novel risk loci for systemic sclerosisThe immunodominant epitope of centromere-associated protein A displays homology with the transcription factor forkhead box E3 (FOXE3).Early systemic sclerosis: marker autoantibodies and videocapillaroscopy patterns are each associated with distinct clinical, functional and cellular activation markers.High IL-17E and low IL-17C dermal expression identifies a fibrosis-specific motif common to morphea and systemic sclerosis.Systemic sclerosis.2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative.Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study.Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients.Autoantibodies recognizing the amino terminal 1-17 segment of CENP-A display unique specificities in systemic sclerosis.European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes.European multicentre study to define disease activity criteria for systemic sclerosis. I. Clinical and epidemiological features of 290 patients from 19 centres.The assessment of the patient with systemic sclerosis.Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effectsItems for developing revised classification criteria in systemic sclerosis: Results of a consensus exerciseAnti-centromere protein A antibodies in systemic sclerosis: Significance and origin.Polymorphism of immunoglobulin enhancer element HS1,2A: allele *2 associates with systemic sclerosis. Comparison with HLA-DR and DQ allele frequencySubspecificities of anticentromeric protein A antibodies identify systemic sclerosis patients at higher risk of pulmonary vascular disease.Adult-onset Still's disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centersEarly systemic sclerosis: short-term disease evolution and factors predicting the development of new manifestations of organ involvement.Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions.Quality of life as measured by the short-form 36 (SF-36) questionnaire in patients with early systemic sclerosis and undifferentiated connective tissue disease.Non-Hodgkin's lymphoma in systemic sclerosis: case and literature review.Clinical correlates of a subset of anti-CENP-A antibodies cross-reacting with FOXE3p53-62 in systemic sclerosis.Prevalence and factors associated with glucocorticoids (GC) use in systemic sclerosis (SSc): a systematic review and meta-analysis of cohort studies and registries.Systemic sclerosis evolution of disease pathomorphosis and survival. Our experience on Italian patients' population and review of the literature.Undifferentiated Connective Tissue Disease at risk for systemic sclerosis (SSc) (so far referred to as very early/early SSc or pre-SSc).Where are we going in the management of interstitial lung disease in patients with systemic sclerosis?New strategies to address the pharmacodynamics and pharmacokinetics of tumor necrosis factor (TNF) inhibitors: A systematic analysis.Update of EULAR recommendations for the treatment of systemic sclerosis.Adult-onset Still's disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients.Outcome of a glucocorticoid discontinuation regimen in patients with inactive systemic sclerosis.Early systemic sclerosis: assessment of clinical and pre-clinical organ involvement in patients with different disease features.A genetic variation located in the promoter region of the UPAR (CD87) gene is associated with the vascular complications of systemic sclerosis.The enhanced liver fibrosis test: a clinical grade, validated serum test, biomarker of overall fibrosis in systemic sclerosis.The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index.Classification of systemic sclerosis.Low-dose aspirin as primary prophylaxis for cardiovascular events in systemic lupus erythematosus: a long-term retrospective cohort study.Clinical correlates of human leucocyte antigen (HLA)-G in systemic sclerosis.What does the clinician need to improve patient care in systemic sclerosis?Cyclophosphamide in systemic sclerosis: still in search of a 'real life' scenario.
P50
Q21144954-99D5AC3B-72D8-413A-B39C-475EC7174A7DQ33632892-1BB99D59-B022-4467-AD1A-9B8245257D54Q33766384-F0239607-2E53-4905-BE31-04FA0C643D83Q34066564-EC48FE73-10DB-4E10-B286-974418D97676Q34163475-42EF3C8F-00DF-426B-BF2F-F432994ECA5AQ34375158-1AFC6F1B-2857-408D-8D85-F53919503258Q34486262-D3FA0127-49DF-4931-8185-56F8D9908E6AQ34559161-920282FB-BC5C-404C-A57E-ECF059CF3A5BQ34684413-467B6FD4-F4CA-4E18-ABA4-12647C8C7B45Q35550511-29010BF3-D60E-4ED7-9166-664485E0990EQ35550528-3B9B8760-BB4F-4DB4-A38B-9B8FA21A0F2FQ35556371-BA6EB0AC-00EB-45F3-86B5-D8EC9AAE7C4FQ35638615-4E1648A6-6830-48B2-A538-5622F86176A3Q35784089-02D15BF8-B506-485A-9DDB-7FA08C6ABDB0Q35802808-A4DAE650-A074-45F8-B530-2445E756639EQ35954658-719980E3-5E34-4E8B-88FF-E061A03B1558Q36060142-F1B6122F-CD3B-431C-A4E7-87F3DACD20C5Q36208563-0A19FEB1-A599-4E7C-A116-834287755072Q36633414-7CEF436E-FDE7-4632-AFC4-B4A345E5332EQ36677277-96CBF79D-F562-4356-A2A8-271D47538624Q36687460-FBD30D0E-2159-49A0-BA7F-315DE40ED540Q37609999-A18D7E6B-FD3B-4EEA-B4B5-DFD37E5F6E4EQ37690559-06631C0A-8012-4CF7-94F2-297D04994789Q38163917-2FB3CBD0-5D1D-4290-8890-0749E567FFBDQ38245569-C05735C0-8C1A-4AC8-A435-44D4DBF69EE1Q38280843-4ABF5F82-4AA3-435D-B75F-D07B4A32C314Q38364657-969F26A4-75EF-4F5A-95DD-8D405A171409Q38488536-CD88AC67-4214-427C-B2DA-6D14676596C1Q38784389-CFC58EB7-6256-464A-96F4-F9DD28D84F4CQ39748097-51323548-0E70-4703-B195-5997C22656D3Q39762874-10E7A780-76C8-4322-A10E-082F1AA084E2Q39938323-9514B7C9-4249-4D14-888D-4C302EFCDE14Q39955870-5B80E26E-785E-49E3-9B8C-97128B37FC43Q40099352-916598A5-7D1C-49D2-85C1-A229F943380AQ40404296-D3497120-CFCB-4AF0-B2A8-3253D433CB29Q40697273-08332AAF-A1E4-4B0E-A38B-147B8A426BD2Q40725518-3B8188DC-97F5-4DAD-88C9-084C18522C2CQ41108942-0342432D-EC32-4669-91DF-538A7BF11734Q42111569-2D3B06D7-BADB-4BB8-8DDD-8AFE154D2D97Q42963326-DE7B5586-142A-40F2-AE34-2486AD3DED02
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Gabriele Valentini
@ast
Gabriele Valentini
@en
Gabriele Valentini
@es
Gabriele Valentini
@nl
type
label
Gabriele Valentini
@ast
Gabriele Valentini
@en
Gabriele Valentini
@es
Gabriele Valentini
@nl
prefLabel
Gabriele Valentini
@ast
Gabriele Valentini
@en
Gabriele Valentini
@es
Gabriele Valentini
@nl
P106
P1153
7102929864
P21
P31
P496
0000-0002-7852-9137